"ESMO 2025: Anticipated Phase II data debut for Eikon’s NSCLC candidate" was originally created and published by Clinical ...

Drug candidates spanning oncology, neurology, rare diseases and more are approaching critical development as the calendar turns to 2026.

In the histology-centric world of cancer medicine, further work is needed to increase genomic testing rates and educate ...

Even after Merck & Co.’s Keytruda has climbed to the top of the industry’s sales charts and racked up dozens of FDA-a | A ...

Merck (MRK) stock is in focus as its blockbuster drug Keytruda as part of a combo regimen hits a secondary goal in a Phase 3 ...

Merck's KEYNOTE-B96 trial shows Keytruda with chemotherapy improves survival in platinum-resistant recurrent ovarian cancer ...

Merck leads U.S. pharma in 2025, but faces Keytruda patent loss by 2028. Click for my look at MRK stock ahead of its upcoming ...

When the organization now called the European Society for Medical Oncology (ESMO) opens its 50th anniversary Congress ...